Eli Lilly and Company (LLY) and EVA Pharma Wednesday announced partnership to expand access to baricitinib to people in 49 low- to middle-income countries in Africa by 2030.
Baricitinib, discovered by Incyte and licensed to Lilly, is approved for the treatment of rheumatoid arthritis, alopecia areata, atopic dermatitis, and COVID-19.
As per the agreement, Lilly will license certain baricitinib manufacturing know-how to EVA Pharma to manufacture and supply the drug across 49 low- to middle-income countries in Africa.
This partnership is part of the Lilly 30x30 initiative, which aims to improve access to quality health care for 30 million people living in resource-limited settings annually by 2030. Since 2021, the companies have been working together on this mission.
As announced in 2022, Lilly and EVA Pharma are also partnering to provide affordable insulin in 56 countries, most of which are low- to middle-income.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.